AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 162 min read$PTCT

Gravier Pierre sold $281K of PTCT

Gravier Pierre (CHIEF FINANCIAL OFFICER) sold 3,494 shares of PTC THERAPEUTICS, INC. (PTCT) at $80.35 ($0.28M total) on 2026-07-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gravier Pierre
Published Jul 16, 2026, 9:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 9:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PTCT
Neutral
high confidence
Mentioned
$PTCT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PTCTNeutralLow
01

Why it matters

For traders, the main actionable element is whether the sale changes sentiment. However, the pre-arranged nature and lack of accompanying company-specific news make it unlikely to drive a sustained repricing.

02

Market read

A CFO insider sale of ~$281K is disclosed, but it is explicitly under a 10b5-1 plan and provides no new fundamental catalyst.

03

What to watch

The article does not disclose whether the sale was part of a broader pattern, tax planning, or diversification, so the signal strength is weak without additional context.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-16 after-hours, reflecting a 2026-07-14 sale.

Background

The article is a SEC Form 4 insider transaction for PTC Therapeutics, reporting a CFO open-market sale executed under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$PTCTNeutralHigh confidence
Context

PTC Therapeutics CFO Gravier Pierre sold 3,494 shares for about $280,742.90 under a pre-arranged 10b5-1 plan on 2026-07-14.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless paired with other new company news.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and the article provides no new guidance, results, or regulatory/contract developments.

Market effects

Sector

Minimal; insider sales under 10b5-1 generally do not reset sector expectations.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be interpreted as liquidity management rather than bearish expectations, especially when executed under a 10b5-1 plan.

Key entities

  • issuer
    PTC THERAPEUTICS, INC.

    Company whose CFO insider sale is disclosed on Form 4.

  • insider
    Gravier Pierre

    Chief Financial Officer reporting an open-market sale of shares.

  • trading mechanism
    10b5-1 plan

    Pre-arranged plan indicating the sale timing was predetermined.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PTCT insider trading history →

Related articles

AUG 27
$PTCTMedAI 8/10

Broader Sephience PKU Data Could Be A Game Changer For PTC Therapeutics (PTCT)

PTC Therapeutics (PTCT) presented new data on its PKU therapy Sephience at the 2026 SSIEM Symposium, showing benefits in lowering phenylalanine levels and diet liberalization across a broad PKU population. The data suggest Sephience could be relevant for a wider spectrum of PKU severity. PTC raised its full-year revenue guidance to US$1.18 billion to US$1.28 billion following stronger Q2 2026 results. Analysts have varying opinions on the company's future revenue and earnings, with some predicti

simplywall.st3 min
AUG 24
$PTCTMedAI 8/10

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

PTC Therapeutics (NASDAQ: PTCT) announced new data on Sephience (sepiapterin) at the 2026 SSIEM Symposium, showing sustained metabolic control, diet liberalization, and a favorable safety profile for PKU patients. Data include significant blood Phe reductions and benefits across patient subgroups. Sephience is approved in the U.S., EU, Japan, and other regions for PKU treatment.

morningstar.com2 min
AUG 24
$PTCTMedAI 8/10

PTC presents Sephience data at metabolic disorders symposium

PTC Therapeutics (PTCT) presented data on Sephience at a metabolic disorders symposium. Clinical trials and real-world data showed significant reductions in blood phenylalanine levels and dietary liberalization in PKU patients. Sephience is approved in the U.S., EU, and Japan. The drug carries warnings about bleeding risk and hypophenylalaninemia. PKU affects about 58,000 people globally.

investing.com2 min
AUG 24
$PTCTMedAI 8/10

PTC Wins Sangamo's Fabry Gene Therapy in Bankruptcy Auction

PTC Therapeutics won a bankruptcy auction for Sangamo Therapeutics' Fabry disease gene therapy, ST-920, paying $111M upfront and up to $100M in milestones. PTC outbid Astellas and TerSera. The deal requires court and regulatory approval. ST-920 showed positive clinical data, supporting an accelerated FDA approval pathway. Eli Lilly also acquired other Sangamo assets for $50M.

cgtlive.com3 min
AUG 13
$PTCTMedAI 9/10

PTC Expands Rare Disease Portfolio With ST-920 Acquisition

PTC Therapeutics (PTCT) agreed to acquire ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics for $111 million upfront plus milestones. PTC cites Phase 1/2 STAAR data and plans an accelerated approval BLA submission, with CMC due Q4 2026 and a 2027 launch. Close expected in Q3 2026.

rttnews.com4 min